Ethos Discovery de novo study
Rapamycin is an immunosuppressive drug that has significant anticancer activity. It has already been approved for use in certain human cancer diagnoses. Reports of Rapamycin activity in canine hemangiosarcoma have been made over several years,
with no clear conclusion.
Recent genomic analysis of hemangiosarcoma in dogs provides a scientific basis for this sporadic activity based on the existence of hemangiosarcoma genotypes that may be uniquely responsive to Rapamycin. Based on its reported tolerability in dogs (alone and in combination with chemotherapy), it is reasonable to now ask if Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma and, more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.
The latest version of this study seeks to understand if a coconut oil-based delivery of Rapamycin would improve the drug’s efficacy in dogs with Hemangiosarcoma.
- Dogs who have had a splenectomy performed within the previous 30 days and were found to have hemangiosarcoma based on histopathologic examination
- Dogs that weigh more than 5kg and less than 45kg
- Peak Veterinary Referral Center, Williston, VT
- VSH – North County, San Marcos, CA
- VSH – Sorrento Valley, San Diego, CA
- WVRC – Waukesha, WI
Enroll or request more information below